Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Fineline Cube Jan 28, 2026
Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Fineline Cube Jan 28, 2026
Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Fineline Cube Jan 28, 2026
Company Drug

NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer

Fineline Cube Dec 2, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...

Company Deals

Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...

Company Drug

Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials

Fineline Cube Dec 2, 2022

China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...

Company Deals

Eli Lilly Ends License for Innovent’s Tyvyt Outside China

Fineline Cube Dec 2, 2022

Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...

Company Deals

Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China

Fineline Cube Dec 2, 2022

Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...

Company Deals Digital

Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine

Fineline Cube Dec 2, 2022

China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...

Company Deals

Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China

Fineline Cube Dec 2, 2022

China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...

Policy / Regulatory

Hainan’s New Regulations on Medical Devices in Boao Lecheng to Take Effect in 2023

Fineline Cube Dec 2, 2022

The “Regulations on the Administration of Medical Devices in Boao Lecheng International Medical Tourism Pilot...

Company Drug

Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA

Fineline Cube Dec 2, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...

Company Medical Device

Sansure Biotech’s Pertussis Detection Kit Approved by NMPA

Fineline Cube Dec 2, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced that it has obtained medical...

Company Drug

Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint

Fineline Cube Dec 2, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that a Phase III clinical study for...

Digital R&D

AI Model for Early Alzheimer’s Detection Using Retinal Photographs Published

Fineline Cube Dec 2, 2022

A joint Singapore-UK-Hong Kong research team has published details of an AI-based deep learning model...

Company Deals

XJTLU and University of Liverpool Launch Joint Centre for Pharmacology and Therapeutics

Fineline Cube Dec 2, 2022

The Suzhou-based Xi’an Jiaotong-Liverpool University (XJTLU) and the UK’s University of Liverpool earlier this month...

Company Deals

Yifan Pharmaceutical Licenses F-627 to Acrotech for US Distribution

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with...

Company Deals Digital

Nans Tech Secures Series A Funding for Brain Dysfunction Digital Therapies

Fineline Cube Dec 1, 2022

Nans Tech, a brain dysfunction digital therapy developer based in Hangzhou, reportedly raised “tens of...

Company Deals

Aclaris Therapeutics Licenses JAK Inhibitor ATI-1777 to Pediatrix for Greater China

Fineline Cube Dec 1, 2022

US-based Aclaris Therapeutics Inc. (NASDAQ: ACRS) and Shanghai firm Pediatrix Therapeutics Inc. entered into a...

Policy / Regulatory

China’s NMPA Issues New GSP Appendix for Drug Retailing Quality Management

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released “Good Supply Practice (GSP) Appendix 6: Quality...

Company Drug

ImmuneOnco Initiates Phase II Clinical Study for CD47 Antibody IMM01

Fineline Cube Dec 1, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study...

Policy / Regulatory

China’s NMPA Seeks Feedback on Drug Quality Management Provisions

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Provisions on the...

Company Deals

Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...

Posts pagination

1 … 541 542 543 … 615

Recent updates

  • Apeloa Partners with MindRank on AI Drug Development Platform
  • China Drug Administration Implementation Regulations Set for May 2026 Launch
  • Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials
  • Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal
  • IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.